Brainstorm Cell Therapeutics, Inc.

NASDAQ:BCLI  
5.24
+0.25 (+5.01%)
Products, Regulatory

Brainstorm Announces Topline Results From NurOwn Phase 3 ALS Study

Published: 11/17/2020 12:38 GMT
Brainstorm Cell Therapuetics Inc (BCLI) - Brainstorm Announces Topline Results From Nurown® Phase 3 Als Study.
Brainstorm Cell Therapeutics Inc - Clinical Trial Did Not Meet Statistical Significance in Primary Efficacy Endpoint.
Brainstorm Cell Therapeutics Inc - Nurown® Showed a Clinically Meaningful Treatment Response Compared to Placebo in a Pre-specified Subgroup.